Ignite Creation Date:
2024-05-06 @ 7:39 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06089044
Status:
COMPLETED
Last Update Posted:
2023-10-18
First Post:
2023-10-12
Brief Title:
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections
Sponsor:
Tourcoing Hospital
Organization:
Tourcoing Hospital
Study Overview
Official Title:
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DALBASAT
Brief Summary:
The aim of this retrospective observational study is to evaluate the efficacy of antibiotic therapy with dalbavancin in patients presenting with infection on prosthetic devices The main questions the study aims to answer are
What is the proportion of patients with early discontinuation of dalbavancin therapy What are the reasons for early discontinuation of antibiotic treatment What adverse events do patients report The study is based on data collected as part of routine care practices
Translated with wwwDeepLcomTranslator free version
What is the proportion of patients with early discontinuation of dalbavancin therapy What are the reasons for early discontinuation of antibiotic treatment What adverse events do patients report The study is based on data collected as part of routine care practices
Translated with wwwDeepLcomTranslator free version
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None